精品国产精品一区二区夜夜嗨,天堂国产欧美一区二区三区,黄色无码在线看,国产精品久久久久久妇女3D

最近搜索:細(xì)胞培養(yǎng) 微生物學(xué) 分子生物 生物化學(xué)
首頁(yè)>>免疫學(xué)>>一抗>>D型-過(guò)氧化酶活化增生受體抗體
D型-過(guò)氧化酶活化增生受體抗體
  • 產(chǎn)品貨號(hào):
    BN41520R
  • 中文名稱(chēng):
    D型-過(guò)氧化酶活化增生受體抗體
  • 英文名稱(chēng):
    Rabbit anti-PPAR delta + beta Polyclonal antibody
  • 品牌:
    Biorigin
  • 貨號(hào)

    產(chǎn)品規(guī)格

    售價(jià)

    備注

  • BN41520R-50ul

    50ul

    ¥1486.00

    交叉反應(yīng):Human,Mouse(predicted:Rat) 推薦應(yīng)用:WB,IHC-P,IHC-F,IF,Flow-Cyt,ELISA

  • BN41520R-100ul

    100ul

    ¥2360.00

    交叉反應(yīng):Human,Mouse(predicted:Rat) 推薦應(yīng)用:WB,IHC-P,IHC-F,IF,Flow-Cyt,ELISA

  • BN41520R-200ul

    200ul

    ¥3490.00

    交叉反應(yīng):Human,Mouse(predicted:Rat) 推薦應(yīng)用:WB,IHC-P,IHC-F,IF,Flow-Cyt,ELISA

產(chǎn)品描述

英文名稱(chēng)PPAR delta + beta
中文名稱(chēng)D型-過(guò)氧化酶活化增生受體抗體
別    名PPAR delta+beta; FAAR; MGC3931; NR1C2; NUC1; NUCI; NUCII; Nuclear hormone receptor 1; Nuclear receptor subfamily 1 group C member 2; Peroxisome proliferative activated receptor delta; Peroxisome proliferator-activated receptor beta (PPAR-beta); Peroxisome proliferator-activated receptor beta; Peroxisome proliferator-activated receptor delta; PPAR beta; PPAR-beta; PPAR-delta; PPAR-? PPARB; PPARD; PPARD_HUMAN.  
研究領(lǐng)域心血管  免疫學(xué)  細(xì)胞膜受體  
抗體來(lái)源Rabbit
克隆類(lèi)型Polyclonal
交叉反應(yīng)Human,  (predicted: Mouse, Rat, )
產(chǎn)品應(yīng)用ELISA=1:5000-10000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1ug/Test IF=1:100-500 (石蠟切片需做抗原修復(fù))
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量48kDa
細(xì)胞定位細(xì)胞核 
性    狀Liquid
濃    度1mg/ml
免 疫 原KLH conjugated synthetic peptide derived from mouse PPAR-delta:2-100/440 
亞    型IgG
純化方法affinity purified by Protein A
儲(chǔ) 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.
PubMedPubMed
產(chǎn)品介紹Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Heterodimer with the retinoid X receptor. Subcellular located at nuclear Tissue specificity: Heart, adrenal and intestine. Belongs to the nuclear hormone receptor family. NR1 subfamily. It Contains 1 nuclear receptor DNA-binding domain.

Function:
Ligand-activated transcription factor. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Has a preference for poly-unsaturated fatty acids, such as gamma-linoleic acid and eicosapentanoic acid. Once activated by a ligand, the receptor binds to promoter elements of target genes. Regulates the peroxisomal beta-oxidation pathway of fatty acids. Functions as transcription activator for the acyl-CoA oxidase gene. Decreases expression of NPC1L1 once activated by a ligand.

Subcellular Location:
Nucleus.

Tissue Specificity:
Ubiquitous with maximal levels in placenta and skeletal muscle.

Similarity:
Belongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain.

SWISS:
P35396

Gene ID:
5467

Database links:

Entrez Gene: 5467 Human

Entrez Gene: 19015 Mouse

Entrez Gene: 25682 Rat

Omim: 600409 Human

SwissProt: Q03181 Human

SwissProt: P35396 Mouse

Unigene: 696032 Human

Unigene: 328914 Mouse

Unigene: 96181 Rat



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

類(lèi)固醇受體(Steroid Receptors)
研究人員指出該分子的功能,極可能就是阻斷心血管免疫發(fā)炎反應(yīng)的訊號(hào)傳遞過(guò)程。PPAR-delta基因是控制肌肉發(fā)展的重要基因,在增加老鼠耐力的同時(shí)還能幫助它燃燒掉脂肪,研究人員發(fā)現(xiàn),對(duì)于與新陳代謝有關(guān)的各項(xiàng)疾病,從心臟病到肥胖癥都有啟發(fā)性的意義,他可以阻止脂肪沉淀在動(dòng)脈壁上,進(jìn)而防止動(dòng)脈硬化癥的發(fā)生,該蛋白參與脂肪代謝、肥胖、糖尿病、動(dòng)脈硬化和癌癥的發(fā)病。
在動(dòng)脈硬化現(xiàn)象發(fā)生的早期,免疫細(xì)胞會(huì)促使血管慢性的發(fā)炎,因而造成血管不斷地吸收和輸送脂肪,進(jìn)而導(dǎo)致脂肪的堆積與血管硬化,而PPAR-delta就像警衛(wèi)分子一樣,時(shí)時(shí)降低發(fā)炎反應(yīng)和抑制動(dòng)脈硬化斑的形成,因此該分子應(yīng)該是相關(guān)藥物研發(fā),相當(dāng)值得切入的目標(biāo)。
研究人員認(rèn)為,這個(gè)發(fā)現(xiàn)將給藥廠(chǎng)研發(fā)治療心血管疾病的新藥提供新的線(xiàn)索。




















image.png

image.png